Milestone Pharmaceuticals (MIST) Capital Expenditures (2018 - 2026)

Milestone Pharmaceuticals (MIST) has reported Capital Expenditures for 7 consecutive years, with $26000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Capital Expenditures rose 136.36% year-over-year to $26000.0; the trailing twelve-month figure through Jun 2026 stood at $356000.0 (up 727.91% YoY), and the FY2025 full-year result was $302000.0, up 815.15% from the prior year.
• Capital Expenditures slipped to $26000.0 in Q2 2026 per MIST's latest filing, from $45000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $283000.0 in Q4 2025 and bottomed at $2000.0 in Q3 2025.
• Historically, Capital Expenditures has averaged $51714.3 across 5 years, with a median of $28500.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Capital Expenditures plunged 82.52% in 2023, then soared 1186.36% in 2025.
• Over 5 years, Capital Expenditures stood at $110000.0 in 2022, then plunged by 71.82% to $31000.0 in 2023, then retreated by 29.03% to $22000.0 in 2024, then jumped by 1186.36% to $283000.0 in 2025, then sank by 90.81% to $26000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $26000.0, $45000.0, and $283000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.